0000000000940064

AUTHOR

Mario Zappia

showing 33 related works from this author

Clinical and magnetic resonance imaging predictors of disease progression in multiple sclerosis: a nine-year follow-up study.

2014

Objective: The objective of this paper is to identify clinical or magnetic resonance imaging (MRI) predictors of long-term clinical progression in a large cohort of multiple sclerosis (MS) patients. Methods: A total of 241 relapsing–remitting (RR) MS patients were included in a nine-year follow-up (FU) study. The reference MRIs were acquired at baseline (BL) as part of a multicenter, cross-sectional, clinical-MRI study. Volumetric MRI metrics were measured by a fully automated, operator-independent, multi-parametric segmentation method. Clinical progression was evaluated as defined by: conversion from RR to secondary progressive (SP) disease course; progression of Expanded Disability Status…

AdultMalemedicine.medical_specialtyMagnetic resonance imaging follow-up multiple sclerosis clinical predictors gray matter atrophypredictormultiple sclerosisDisease courseDisability EvaluationMultiple Sclerosis Relapsing-RemittingInternal medicinefollow-upmedicineHumansSecondary progressiveExpanded Disability Status Scalemedicine.diagnostic_testbusiness.industryMultiple sclerosisDisease progressionFollow up studiesMagnetic resonance imagingclinical predictorsMiddle Agedmedicine.diseaseMagnetic Resonance Imaginggray matter atrophyCross-Sectional StudiesNeurologymultiple sclerosiDisease ProgressionSettore MED/26 - NeurologiaFemaleNeurology (clinical)businessNuclear medicineClinical progressionMRIFollow-Up StudiesMultiple sclerosis (Houndmills, Basingstoke, England)
researchProduct

Parkin gene analysis in late onset Parkinson's disease families

2004

researchProduct

Factors influencing psychological well-being in patients with Parkinson's disease.

2017

Background Both motor and non-motor symptoms could contribute to significant deterioration of psychological well-being in patients with Parkinson's disease (PD). However, its assessment has been only indirectly evaluated using tools based on health-related quality of life (HRQoL), such as the PDQ-39 scale. Objectives To evaluate psychological well-being in PD using a specific tool of assessment, the Psychological Well-being Scale (PWS), and its clinical correlates. Methods This article reports data of patients' perception of health state, as measured by means of the PWS, from an epidemiological, cross-sectional study conducted in Italian PD patients (FORTE Study). We tested possible relatio…

Genetics and Molecular Biology (all)MaleParkinson's diseaseEmotionsPoison controlSocial Scienceslcsh:MedicinePathology and Laboratory MedicineBiochemistrySeverity of Illness IndexAged; Depression; Fatigue; Female; Humans; Italy; Male; Middle Aged; Parkinson Disease; Psychiatric Status Rating Scales; Quality of Life; Severity of Illness Index; Surveys and Questionnaires; Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)0302 clinical medicineMathematical and Statistical TechniquesQuality of lifeSurveys and QuestionnairesMedicine and Health SciencesMedicinePsychologySurveys and Questionnaire030212 general & internal medicinelcsh:ScienceDepression (differential diagnoses)FatigueMultidisciplinaryMovement DisordersDepressionNeurodegenerative DiseasesParkinson DiseaseMiddle AgedPsychiatric Status Rating ScalehumanitiesNeurologyItalyPhysical SciencesFemaleStatistics (Mathematics)Clinical psychologyResearch ArticleHumanResearch and Analysis Methods03 medical and health sciencesSigns and SymptomsDiagnostic MedicineSeverity of illnessInjury preventionMental Health and PsychiatryHumansStatistical MethodsAgedPsychiatric Status Rating Scalesparkinson's disease quality of lifeAnalysis of VarianceBiochemistry Genetics and Molecular Biology (all)business.industryMood Disorderslcsh:RBeck Depression InventoryBiology and Life Sciencesmedicine.diseaseHealth CareAgricultural and Biological Sciences (all)Psychological well-beingAged; Depression; Fatigue; Female; Humans; Italy; Male; Middle Aged; Parkinson Disease; Psychiatric Status Rating Scales; Quality of Life; Severity of Illness Index; Surveys and QuestionnairesQuality of Lifelcsh:QbusinessSleep Disorders030217 neurology & neurosurgeryMathematicsPLoS ONE
researchProduct

Myocardial 123metaiodobenzylguanidine uptake in genetic Parkinson's disease.

2008

Myocardial (123)Metaiodobenzylguanidine (MIBG) enables the assessment of postganglionic sympathetic cardiac innervation. MIBG uptake is decreased in nearly all patients with Parkinson's disease (PD). Our objective was to evaluate MIBG uptake in patients with genetic PD. We investigated MIBG uptake in 14 patients with PD associated with mutations in different genes (Parkin, DJ-1, PINK], and leucine-rich repeat kinase 2 -LRRK2), in 15 patients with idiopathic PD, and 10 control subjects. The myocardial MIGB uptake was preserved in 3 of the 4 Parkin-associated Parkinsonisms, in I of the 2 patients with DJ-1 mutations, in 1 of the 2 brothers with PINK] mutations, in 3 of the 6 unrelated patient…

AdultMalemedicine.medical_specialtyParkinson's diseaseGenotypeUbiquitin-Protein LigasesDNA Mutational AnalysisProtein Deglycase DJ-1PINK1Gene mutationProtein Serine-Threonine Kinasesmedicine.disease_causeLeucine-Rich Repeat Serine-Threonine Protein Kinase-2Severity of Illness IndexParkinCentral nervous system diseaseDiagnosis DifferentialDegenerative diseaseParkinsonian DisordersInternal medicineSurveys and QuestionnairesmedicineHumansPoint MutationPromoter Regions GeneticGenetic PD Myocardial scintigraphyOncogene ProteinsTomography Emission-Computed Single-PhotonMutationMovement Disordersbusiness.industryMyocardiumIntracellular Signaling Peptides and ProteinsParkinson DiseaseGalvanic Skin ResponseMiddle Agedmedicine.diseaseLRRK2nervous system diseases3-IodobenzylguanidineEndocrinologyNeurologySettore MED/26 - NeurologiaFemaleNeurology (clinical)RadiopharmaceuticalsbusinessProtein KinasesMovement disorders : official journal of the Movement Disorder Society
researchProduct

Clinical-Instrumental patterns of neurodegeneration in Essential Tremor: A data-driven approach

2021

Abstract Introduction Essential Tremor (ET) is increasingly recognized as a complex disorder with additional clinical signs other than tremor. It is still unknown whether a unique pathophysiologic or neurodegenerative process underlies progression and prognosis of the disease. The aim of the study was to identify ET phenotypes through a clinical-instrumental data-driven approach and to characterize possible patterns of neurodegeneration. Methods ET patients were categorized using spatio-temporal and kinematic variables related to mobility and dynamic stability processed by motion transducers. Differences between the identified groups in clinical-demographic variables, neuropsychological per…

0301 basic medicineRetinal degenerationMalemedicine.medical_specialtyHead tremorTimed up and go testRetina03 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitation80 and overNeurologicMedicineHumansCognitive DysfunctionGait DisordersCognitive declineNeurodegenerationTomographyGait Disorders NeurologicAgedAged 80 and overEssential tremorOptical coherence tomographybusiness.industryNeuropsychologyCognitionNeurodegenerative Diseasesmedicine.diseaseAction tremorGait030104 developmental biologyNeurologyOptical CoherenceEssential tremorFemale[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieNeurology (clinical)Geriatrics and Gerontologybusiness030217 neurology & neurosurgeryTomography Optical Coherence
researchProduct

Neurofunctional correlates of attention rehabilitation in Parkinson's disease: an explorative study

2014

The effectiveness of cognitive rehabilitation (CR) in Parkinson’s disease (PD) is in its relative infancy, and nowadays there is insufficient information to support evidence-based clinical protocols. This study is aimed at testing a validated therapeutic strategy characterized by intensive computer-based attention-training program tailored to attention deficits. We further investigated the presence of synaptic plasticity by means of functional magnetic resonance imaging (fMRI). Using a randomized controlled study, we enrolled eight PD patients who underwent a CR program (Experimental group) and seven clinically/demographically-matched PD patients who underwent a placebo intervention (Contro…

Malemedicine.medical_specialtyBrain activity and meditationPrefrontal CortexDermatologyNeuropsychological TestsStatistical parametric mappingPhysical medicine and rehabilitationParietal LobemedicineHumansAttentionSingle-Blind MethodEffects of sleep deprivation on cognitive performanceCognitive rehabilitation therapyPrincipal Component AnalysisNeuronal PlasticityResting state fMRImedicine.diagnostic_testCognitionParkinson DiseaseGeneral MedicineMiddle AgedMagnetic Resonance ImagingDorsolateral prefrontal cortexPsychiatry and Mental healthParkinson disease rehabilitationmedicine.anatomical_structureMemory Short-TermPhenotypeSpace PerceptionTherapy Computer-AssistedVisual PerceptionFemaleSettore MED/26 - NeurologiaNeurology (clinical)Nerve NetFunctional magnetic resonance imagingPsychologyCognition DisordersNeurosciencePsychomotor Performance
researchProduct

Cognitive impairment and levodopa induced dyskinesia in Parkinson’s disease: a longitudinal study from the PACOS cohort

2021

AbstractAim of the study was to evaluate possible associations between cognitive dysfunctions and development of Levodopa Induced Dyskinesia (LID). PD patients from the Parkinson’s disease Cognitive impairment Study cohort who underwent a baseline and follow-up neuropsychological evaluations were enrolled. Mild Cognitive Impairment (PD-MCI) was diagnosed according to MDS level II criteria. The following cognitive domains were evaluated: episodic memory, attention, executive function, visuo-spatial function and language. A domain was considered as impaired when the subject scored 2 standard deviation below normality cut-off values in at least one test for each domain. Levodopa equivalent dos…

Male0301 basic medicineDyskinesia Drug-InducedLevodopamedicine.medical_specialtyParkinson's diseaseScienceNeuropsychological TestsSeverity of Illness IndexArticleCohort StudiesLevodopaExecutive Function03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansAttentionCognitive DysfunctionLongitudinal StudiesAgedProportional Hazards ModelsLevodopa-induced dyskinesiaMultidisciplinarybusiness.industryQRNeuropsychologyParkinson DiseaseCognitionMiddle Agedmedicine.diseaseAged Attention Cognitive Dysfunction Cohort Studies Dyskinesia Drug-Induced Executive Function Female Humans Levodopa Longitudinal Studies Male Middle Aged Neuropsychological Tests Parkinson Disease Proportional Hazards Models Severity of Illness Index030104 developmental biologyNeurologyRisk factorsDyskinesiaCohortMedicineFemalemedicine.symptombusiness030217 neurology & neurosurgerymedicine.drugCohort studyScientific Reports
researchProduct

Mutation analysis of the SPG4 gene in Italian patients with pure and complicated forms of spastic paraplegia

2010

Mutations in the SPG4 gene are the most common causes of hereditary spastic paraplegia (HSP) accounting for up to 40% of autosomal dominant (AD) forms and 12-18% of sporadic cases. The phenotype associated with HSP due to mutations in the SPG4 gene tends to be pure. There is increasing evidence, however, of patients with complicated forms of spastic paraplegia in which SPG4 mutations were identified. A cohort of 38 unrelated Italian patients with spastic paraplegia, of which 24 had a clear dominant inheritance and 14 were apparently sporadic, were screened for mutations in the SPG4 gene.We identified 11 different mutations, six of which were novel (p.Glu143GlyfsX8, p.Tyr415X, p.Asp548Asn, c…

MaleSpastinDNA Mutational AnalysisHereditary spastic paraplegiaEXON DELETIONSGene mutationmedicine.disease_causeSpastinFAMILIESCohort StudiesExonGenotypeSpasticMutation frequencyChild3' Untranslated RegionsChromatography High Pressure LiquidAdenosine TriphosphatasesGeneticsMutationHereditary spastic paraplegia SPG4Reverse Transcriptase Polymerase Chain ReactionMutation analysiExonsMiddle AgedMLPAPhenotypeMutation analysisItalyNeurologySettore MED/26 - NeurologiaFemaleAdultAdolescentGenotypeHereditary spastic paraplegia3 ' UTR3′ UTRMutation MissenseFREQUENTSPG4CLASSIFICATIONYoung AdultmedicineHumansAgedParaplegiaSPECTRUMbusiness.industrymedicine.diseaseNeurology (clinical)businessCOLLECTIONEXPRESSION ANALYSISGene Deletion
researchProduct

DJ-1 gene in late-onset recessive Parkinson's Disease

2004

researchProduct

Prevalence of Parkinson's disease and other types of parkinsonism in the Aeolian Archipelago, Sicily.

2007

Abstract Objective To estimate prevalence of Parkinson's disease (PD) and other types of parkinsonism in the Aeolian Archipelago, Sicily. Methods We studied the frequency of PD and other types of parkinsonism in the Aeolian Archipelago (population 13,431). All potential cases were identified from available medical information sources. To ensure the completeness of the case-findings, a screening questionnaire was also mailed to residents aged 40 years and over. Subjects were considered prevalent if they fulfilled the SNES diagnostic criteria for PD, on prevalence day (January 1, 2001). Results We identified 17 patients with parkinsonism from medical sources, and 4 from mail-survey. Prevalenc…

AdultMalePediatricsmedicine.medical_specialtyParkinson's diseasePopulationMedical informationDiseaseSeverity of Illness IndexParkinsonian DisordersEpidemiologyEpidemiology parkinsonism prevalencemedicineHumanseducationSicilyAeolian archipelagoAgedAged 80 and overeducation.field_of_studybusiness.industryParkinsonismParkinson DiseaseMiddle Agedmedicine.diseaseHealth SurveysScreening questionnaireNeurologyPhysical therapyFemaleNeurology (clinical)Geriatrics and GerontologybusinessParkinsonismrelated disorders
researchProduct

Lesion load may predict long-term cognitive dysfunction in multiple sclerosis patients

2015

Background: Magnetic Resonance Imaging (MRI) techniques provided evidences into the understanding of cognitive impairment (CIm) in Multiple Sclerosis (MS). Objectives: To investigate the role of white matter (WM) and gray matter (GM) in predicting long-term CIm in a cohort of MS patients. Methods: 303 out of 597 patients participating in a previous multicenter clinical-MRI study were enrolled (49.4% were lost at follow-up). The following MRI parameters, expressed as fraction (f) of intracranial volume, were evaluated: cerebrospinal fluid (CSF-f), WM-f, GM-f and abnormal WM (AWM-f), a measure of lesion load. Nine years later, cognitive status was assessed in 241 patients using the Symbol Dig…

EMTREE medical terms: Articlerecalllcsh:MedicineAudiologyNeuropsychological TestsNerve Fibers Myelinated030218 nuclear medicine & medical imagingCohort Studies0302 clinical medicinecognitive defectnuclear magnetic resonance imaginglcsh:ScienceModified Card Sorting TestMultidisciplinaryneuroimagingSemantically Related Word List TestMultiple Sclerosis Cognitive Dysfunction MRImedicine.diagnostic_testpredictive valueBrainCognitionNeuropsychological testgray matterMiddle AgedPrognosisMagnetic Resonance ImagingMemory Short-Termfemalebrain sizemultiple sclerosiCohortDisease ProgressionSettore MED/26 - Neurologiawhite matterResearch ArticleAdultmedicine.medical_specialtyMultiple SclerosisPaced Auditory Serial Addition Testverbal memorycerebrospinal fluidworking memory03 medical and health sciencesmalemedicineHumanscontrolled studyhumanRecallbusiness.industryMultiple sclerosislcsh:RMagnetic resonance imagingmedicine.diseasemajor clinical studyattentionexecutive functionSymbol Digit Modalities TestPaced Auditory Serial Addition Testneuropsychological testlcsh:QVerbal memorybusinessCognition Disorders030217 neurology & neurosurgeryFollow-Up Studies
researchProduct

Parkin gene analysis in late onset autosomal recessive Parkinson's Disease

2004

researchProduct

Mild behavioral impairment in Parkinson's disease: Data from the Parkinson's disease cognitive impairment study (PACOS)

2019

Neuropsychiatric symptoms (NPS) have been frequently described in Parkinson's disease (PD), even in the earliest stages of the disease. Recently the construct of mild behavioral impairment (MBI) has been proposed as an at-risk state for incident cognitive decline and dementia. The aim of the present study is to evaluate the prevalence and associated factors of MBI in PD. Cross-sectional data from 429 consecutive PD patients enrolled in the PArkinson's disease COgnitive impairment Study (PACOS) were included in the study. All subjects underwent neuropsychological assessment, according to the MDS Level II criteria. NPS were evaluated with the Neuropsychiatric Inventory. Multivariate logistic …

0301 basic medicineMalemedicine.medical_specialtyParkinson's diseaseParkinson's diseaseMild behavioral impairmentNeuropsychiatric symptomDiseaseCognitive impairment; Mild behavioral impairment; Neuropsychiatric symptoms; Parkinson's disease; Prevalence; Neuroscience (all); Clinical Psychology; Geriatrics and Gerontology; Psychiatry and Mental HealthNeuropsychological TestsLogistic regressionSeverity of Illness Index03 medical and health sciences0302 clinical medicineInternal medicinemedicinePrevalenceDementiaHumansCognitive DysfunctionNeuropsychological assessmentCognitive declineStage (cooking)Cognitive impairmentAgedNeuroscience (all)medicine.diagnostic_testbusiness.industryGeneral NeuroscienceParkinson DiseaseGeneral MedicineMiddle Agedmedicine.diseaseNeuropsychiatric symptomsClinical Psychology030104 developmental biologyCross-Sectional StudiesCognitive impairmentPsychiatry and Mental HealthFemaleGeriatrics and Gerontologybusiness030217 neurology & neurosurgery
researchProduct

Transcranial random noise stimulation over the primary motor cortex in PD-MCI patients: a crossover, randomized, sham-controlled study

2020

AbstractMild cognitive impairment (MCI) is a very common non-motor feature of Parkinson’s disease (PD) and the non-amnestic single-domain is the most frequent subtype. Transcranial random noise stimulation (tRNS) is a non-invasive technique, which is capable of enhancing cortical excitability. As the main contributor to voluntary movement control, the primary motor cortex (M1) has been recently reported to be involved in higher cognitive functioning. The aim of this study is to evaluate the effects of tRNS applied over M1 in PD-MCI patients in cognitive and motor tasks. Ten PD-MCI patients, diagnosed according to the Movement Disorder Society, Level II criteria for MCI, underwent active (re…

0301 basic medicinemedicine.medical_specialtyParkinson's diseaseNeurologyPrefrontal CortexNeurology and Preclinical Neurological Studies - Original ArticleTranscranial Direct Current Stimulation03 medical and health sciencesCognition0302 clinical medicinePhysical medicine and rehabilitationSettore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat.medicineMemory spanHumansCognitive DysfunctionBiological Psychiatrybusiness.industryMotor CortexParkinson DiseaseCognitionmedicine.diseaseCognitive impairment Motor cortex Parkinson’s disease Transcranial random noise stimulationTranscranial random noise stimulationDorsolateral prefrontal cortexPsychiatry and Mental healthCognitive impairment030104 developmental biologymedicine.anatomical_structureNeurologyParkinson’s diseaseSettore MED/26 - NeurologiaNeurology (clinical)Primary motor cortexbusiness030217 neurology & neurosurgeryStroop effectMotor cortexJournal of Neural Transmission
researchProduct

Executive functioning and serum lipid fractions in Parkinson’s disease—a possible sex-effect: the PACOS study

2022

AbstractThe association between dyslipidemia and cognitive performance in Parkinson’s disease (PD) patients still needs to be clarified. Aim of the study was to evaluate the presence of possible associations between serum lipids fractions and executive dysfunction also exploring the sex-specific contribute of lipids level on cognition. Patients from the PACOS cohort, who underwent a complete serum lipid profile measures (total cholesterol-TC, low-density lipoprotein cholesterol-LDL, high-density lipoprotein cholesterol-HDL and triglycerides-TG) were selected. Adult Treatment Panel III guidelines of the National Cholesterol Education Program were used to classify normal/abnormal lipid fracti…

AdultMaleCholesterol HDLParkinson DiseaseCholesterol LDLMiddle AgedLipidsExecutive functionsPsychiatry and Mental healthCholesterolNeurologyParkinson’s diseaseHumansFemaleSettore MED/26 - Neurologialipids (amino acids peptides and proteins)Neurology (clinical)TriglyceridesBiological PsychiatryAgedJournal of Neural Transmission
researchProduct

Mild cognitive impairment in Parkinson’s disease: the Parkinson’s disease cognitive study (PACOS)

2018

Approximately 30% of Parkinson's disease (PD) patients show impaired cognitive performance, which is suggestive of Mild Cognitive Impairment (MCI), representing a predictor of dementia, especially when present at diagnosis. The objective of the study was to evaluate the frequency and clinical predictors of MCI in a large hospital-based cohort of PD patients. We collected cross-sectional data from the Parkinson's disease cognitive impairment study (PACOS), a multicenter study involving two Movement Disorder centers, which are located in south Italy. The PD subjects were diagnosed according to the UK Brain Bank criteria and they underwent an extensive neuropsychological assessment. PD-MCI was…

Male0301 basic medicinemedicine.medical_specialtyNeurologyParkinson's diseaseEpidemiologyParkinson's diseaseNeuropsychological TestsLogistic regressionSeverity of Illness Index03 medical and health sciences0302 clinical medicineInternal medicinemental disordersEpidemiologyOdds RatioPrevalenceHumansMedicineDementiaCognitive DysfunctionParkinsonâ s diseaseEffects of sleep deprivation on cognitive performanceNeuropsychological assessmentAge of OnsetCognitive impairment; Epidemiology; Parkinson’s disease; Prevalence; Neurology; Neurology (clinical)AgedRetrospective Studiesmedicine.diagnostic_testbusiness.industryParkinson Diseasemedicine.diseasenervous system diseasesCross-Sectional StudiesCognitive impairment030104 developmental biologyNeurologyMultivariate AnalysisCohortEducational StatusSettore MED/26 - NeurologiaFemaleAmnesiaNeurology (clinical)businesshuman activities030217 neurology & neurosurgeryJournal of Neurology
researchProduct

First detection of SARS-CoV-2 A.23.1 sub-lineage in migrants arriving to Italy via the Mediterranean Sea and public health implications

2021

COVID-19 Mediterranean sea Migrants Molecular surveillance NGS Phylogeny analysis Public health SARS-CoV-2 Vaccination programs2019-20 coronavirus outbreakmedicine.medical_specialtyLineage (genetic)Coronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Vaccination programsMigrantsArticlePhylogeny analysisMediterranean seamedicineHumansPhylogenyTransients and MigrantsPublic healthSARS-CoV-2Public healthPublic Health Environmental and Occupational HealthCOVID-19VirologyInfectious DiseasesGeographyItalyMolecular surveillanceNGSMediterranean seaTravel Medicine and Infectious Disease
researchProduct

Incidence of Mild Cognitive Impairment and Dementia in Parkinson's Disease: The Parkinson's Disease Cognitive Impairment Study.

2018

Background: Cognitive impairment in Parkinson's disease (PD) includes a spectrum varying from Mild Cognitive Impairment (PD-MCI) to PD Dementia (PDD). The main aim of the present study is to evaluate the incidence of PD-MCI, its rate of progression to dementia, and to identify demographic and clinical characteristics which predict cognitive impairment in PD patients. Methods: PD patients from a large hospital-based cohort who underwent at least two comprehensive neuropsychological evaluations were retrospectively enrolled in the study. PD-MCI and PDD were diagnosed according to the Movement Disorder Society criteria. Incidence rates of PD-MCI and PDD were estimated. Clinical and demographic…

0301 basic medicineAgingmedicine.medical_specialtyParkinson's diseaseCognitive NeuroscienceParkinson's diseasebehavioral disciplines and activitieslcsh:RC321-57103 medical and health sciences0302 clinical medicinemild cognitive impairmentInternal medicinemental disordersMedicineDementiaNeuropsychological assessmentMild cognitive impairment (MCI)lcsh:Neurosciences. Biological psychiatry. NeuropsychiatryOriginal Researchmedicine.diagnostic_testbusiness.industryProportional hazards modelIncidence (epidemiology)Neuropsychologymedicine.diseasenervous system diseasesneuropsychological assessment030104 developmental biologyCohortParkinson’s diseaseincidencebusiness030217 neurology & neurosurgeryNeurosciencedementiaFrontiers in aging neuroscience
researchProduct

Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience

2019

Teriflunomide (TRF) and Dimethyl fumarate (DMF) are licensed drugs for relapsing-remitting Multiple Sclerosis (RRMS). We aimed to compare the rate and the time to discontinuation among persons with RRMS (pwRRMS), newly treated with TRF and DMF. A retrospective study on prospectively collected data was performed in nine tertiary MS centers, in Italy. The 24-month discontinuation rate in the two cohorts was the primary study outcome. We also assessed the time to discontinuation and reasons of therapy withdrawn. Discontinuation of TRF and DMF was defined as a gap of treatment ≥ 60 days. A cohort of 903 pwRRMS (316 on TRF and 587 on DMF) was analyzed. During 24 months of follow-up, pwRRMS on TR…

Adultmedicine.medical_specialtyDiscontinuation rateTime FactorsToluidinesPopulationHydroxybutyratesRelapsing-RemittingDimethyl fumarateMultiple sclerosis03 medical and health scienceschemistry.chemical_compound0302 clinical medicineMultiple Sclerosis Relapsing-RemittingInternal medicineTeriflunomideNitrilesTeriflunomidemedicineHumansMultiple sclerosi030212 general & internal medicineeducationRetrospective Studieseducation.field_of_studyDimethyl fumaratebusiness.industryProportional hazards modelMultiple sclerosisDimethyl fumarate; Discontinuation rate; Multiple sclerosis; Real-life; Teriflunomide; Neurology; Neurology (clinical)Real-lifeRetrospective cohort studyMiddle Agedmedicine.diseaseDiscontinuationchemistryItalyNeurologyCrotonatesCohortDimethyl fumarate; Discontinuation rate; Multiple sclerosis; Real-life; Teriflunomide; Adult; Crotonates; Dimethyl Fumarate; Follow-Up Studies; Humans; Immunosuppressive Agents; Italy; Middle Aged; Multiple Sclerosis Relapsing-Remitting; Retrospective Studies; Time Factors; ToluidinesNeurology (clinical)business030217 neurology & neurosurgeryImmunosuppressive AgentsFollow-Up Studies
researchProduct

Cardiovascular autonomic function and MCI in Parkinson's disease

2019

Abstract Introduction dysautonomic dysfunction and cognitive impairment represent the most disabling non-motor features of Parkinson's Disease (PD). Recent evidences suggest the association between Orthostatic Hypotension (OH) and PD-Dementia. However, little is known on the interactions between cardiovascular dysautonomia and Mild Cognitive Impairment (MCI). We aimed to evaluate the association between cardiovascular dysautonomia and MCI in patients with PD. Methods non-demented PD patients belonging to the PACOS cohort underwent a comprehensive instrumental neurovegetative assessment including the study of both parasympathetic and sympathetic function (30:15 ratio, Expiratory-Inspiratory …

Male0301 basic medicineAutonomic functionmedicine.medical_specialtyAutonomic systemParkinson's diseaseParkinson's diseasePrimary DysautonomiasDiseaseHypotension Orthostatic03 medical and health sciencesOrthostatic vital signs0302 clinical medicineInternal medicineHumansMedicineCognitive DysfunctionCognitive impairmentAgedRetrospective Studiesbusiness.industryMild cognitive impairmentDysautonomiaParkinson DiseaseMiddle Agedmedicine.disease030104 developmental biologyNeurologyCohortCardiologyFemaleCardiovascular dysautonomiaNeurology (clinical)Level iiGeriatrics and Gerontologymedicine.symptombusiness030217 neurology & neurosurgery
researchProduct

Changes in Motor, Cognitive, and Behavioral Symptoms in Parkinson's Disease and Mild Cognitive Impairment During the COVID-19 Lockdown

2020

Objective: The effects of the COVID-19 lockdown on subjects with prodromal phases of dementia are unknown. The aim of this study was to evaluate the motor, cognitive, and behavioral changes during the COVID-19 lockdown in Italy in patients with Parkinson's disease (PD) with and without mild cognitive impairment (PD-MCI and PD-NC) and in patients with MCI not associated with PD (MCInoPD).Methods: A total of 34 patients with PD-NC, 31 PD-MCI, and 31 MCInoPD and their caregivers were interviewed 10 weeks after the COVID-19 lockdown in Italy, and changes in cognitive, behavioral, and motor symptoms were examined. Modified standardized scales, including the Neuropsychiatric Inventory (NPI) and t…

medicine.medical_specialtyMultivariate analysisActivities of daily livingParkinson's diseaselcsh:RC435-571behavioral symptomsParkinson's diseaseDiseasebehavioral symptoms caregiver burden cognitive impairment COVID-19 motor impairment Parkinson's disease quarantinemotor impairment03 medical and health sciences0302 clinical medicineRating scalelcsh:PsychiatryInternal medicinemental disordersmedicineDementiaOriginal Researchcognitive impairmentPsychiatrycaregiver burden030214 geriatricsbusiness.industryquarantineCOVID-19CognitionCaregiver burdenmedicine.diseasePsychiatry and Mental healthbusiness030217 neurology & neurosurgeryFrontiers in Psychiatry
researchProduct

Computer-assisted cognitive remediation for Parkinson’s disease

2012

computer-assisted cognitive training parkinson's diseaseSettore MED/26 - Neurologia
researchProduct

Morphometric magnetic resonance imaging cortico-subcortical features in Parkinson's disease with mild cognitive impairment

2022

Background and purpose Parkinson's disease (PD) patients with cognitive impairment undergo progressive atrophy of several cortical and subcortical areas. The aim was to study the magnetic resonance imaging (MRI) morphometric features of PD patients with mild cognitive impairment (MCI). Methods Patients from the Parkinson's Disease Cognitive Impairment Study (PACOS) cohort with an available structural volumetric brain MRI and morphometric measurements of the midbrain and pons areas, middle cerebellar peduncle, superior cerebellar peduncle width and midbrain anteroposterior diameter (A-Pdiam) were included. MCI was diagnosed according to the Movement Disorder Society level II criteria. Additi…

Cerebral CortexMaleParkinson's diseaseParkinson DiseasemidbrainNeuropsychological TestsbrainstemNeurologyParkinson’s diseaseHumansmagnetic resonance imagingCognitive DysfunctionFemaleSettore MED/26 - NeurologiaNeurology (clinical)Atrophycognitive impairment
researchProduct

Influence of Drugs on Mild Cognitive Impairment in Parkinson’s Disease: Evidence from the PACOS Study

2022

Background: Polytherapy and the anticholinergic activity of several drugs negatively influence cognition in the elderly. However, little is known on the effect on Mild Cognitive Impairment (MCI) in Parkinson’s Disease (PD). Methods: Patients with PD belonging to the baseline PACOS cohort with full pharmacological data, have been included in this study. MCI diagnosis was made according to the MDS level II criteria. Polytherapy was defined as patients assuming ≥6 drugs. Anticholinergic burden has been calculated using the Anticholinergic Drug Scale (ADS). Molecules have been classified according to the ATC classification. Association with MCI has been assessed with a multivariate logistic re…

PharmacologyParkinson DiseaseGeneral MedicineMiddle AgedNeuropsychological TestspolytherapydrugsCholinergic Antagonistsanticholinergic burdenPsychiatry and Mental healthmild cognitive impairmentNeurologyParkinson’s diseaseHumansSettore MED/26 - NeurologiaCognitive DysfunctionPharmacology (medical)Neurology (clinical)polypharmacyAgedCurrent Neuropharmacology
researchProduct

Neuroanatomical changes in early Parkinson’s disease with mild cognitive impairment: a VBM study; the Parkinson’s Disease Cognitive Impairment Study …

2021

Introduction: Mild cognitive impairment (MCI) is common in Parkinson’s disease (PD), but the underlying pathological mechanism has not been fully understood. Voxel-based morphometry could be used to evaluate regional atrophy and its relationship with cognitive performances in early PD-MCI. Patients and Methods: One hundred and six patients with PD were recruited from a larger cohort of patients, the Parkinson’s Disease Cognitive Impairment Study (PaCoS). Subject underwent a T1-3D MRI and a complete clinical and neuropsychological evaluation. Patients were divided into PD with normal cognition (PD-NC) and PD-MCI according to the MDS level II criteria–modified for PD-MCI. A subgroup of early …

medicine.medical_specialtyParkinson's diseasePrecuneusInferior frontal gyrusDermatologyNeuropsychological TestsAudiologybehavioral disciplines and activitiesVoxel-based morphometry (VBM)Angular gyrus03 medical and health sciences0302 clinical medicinemental disordersmedicineHumansCognitive DysfunctionMagnetic resonance imaging (MRI)030212 general & internal medicineGray MatterMild cognitive impairment (MCI)business.industryNeuropsychologyBrainSettore MED/37 - NeuroradiologiaGeneral MedicineFrontal gyrusmedicine.diseaseMagnetic Resonance ImagingParkinson diseasePsychiatry and Mental healthmedicine.anatomical_structurenervous systemSuperior frontal gyrusSettore MED/26 - NeurologiaNeurology (clinical)Settore MED/36 - Diagnostica Per Immagini E RadioterapiabusinessMild cognitive impairment (MCI)030217 neurology & neurosurgeryNeurological Sciences
researchProduct

Electrocortical networks in Parkinson's disease patients with Mild Cognitive Impairment. The PaCoS study

2019

Abstract Introduction Parkinson's Disease (PD) is frequently associated with cognitive dysfunction ranging from Mild Cognitive Impairment (PD-MCI) to dementia. Few electrophysiological studies are available evaluating potential pathogenetic mechanisms linked to cognitive impairment in PD since its initial phases. The objective of the study is to analyze electrocortical networks related with cognitive decline in PD-MCI for identifying possible early electrophysiological markers of cognitive impairment in PD. Methods From the PaCoS (Parkinson's disease Cognitive impairment Study) cohort, a sample of 102 subjects including 46 PD-MCI and 56 PD with normal cognition (PD-NC) was selected based on…

Male0301 basic medicinemedicine.medical_specialtyParkinson's diseaseQuantitative EEGElectroencephalographyAudiology03 medical and health sciences0302 clinical medicinemental disordersmedicineHumansDementiaCognitive DysfunctionNeuropsychological assessmentCognitive declineTomographyAgedElectrocortical networkElectrocortical networksmedicine.diagnostic_testbusiness.industryParietal lobeMild cognitive impairmentElectroencephalographyParkinson DiseaseCognitionMiddle Agedmedicine.disease030104 developmental biologyNeurologyFrontal lobeDisease ProgressionFemaleNeurology (clinical)Nerve NetElectrocortical networks; Mild cognitive impairment; Parkinson's disease; Quantitative EEG; Neurology; Geriatrics and Gerontology; Neurology (clinical)Geriatrics and GerontologyOccipital lobebusiness030217 neurology & neurosurgeryParkinsonism & Related Disorders
researchProduct

Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multi…

2018

BACKGROUND: The aim of the study was to evaluate the achievement of 'no evidence of disease activity' (NEDA) over a 12-month period in a large multicenter population with relapsing remitting multiple sclerosis (RRMS) treated with delayed-release dimethyl fumarate (DMF) and teriflunomide (TRF) using a propensity-score adjustment. METHODS: A time-to-event method was used to determine the percentages of patients with RRMS (pwRRMS) in both groups achieving NEDA 3 (no relapses, no 12-week confirmed disability progression, and no new T2/gadolinium-enhancing brain lesions). We described the safety profile of the investigated drugs. RESULTS: Of the 587 pwRRMS treated with DMF and the 316 pwRRMS tre…

safetymedicine.medical_specialtydimethyl fumarate; efficacy; no evidence of disease activity 3; safety; teriflunomide; pharmacology; neurology; neurology (clinical)Populationefficacylcsh:RC346-429Disease activity03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineTeriflunomideteriflunomideMedicine030212 general & internal medicineno evidence of disease activity 3educationlcsh:Neurology. Diseases of the nervous systemOriginal ResearchPharmacologyeducation.field_of_studydimethyl fumarateDimethyl fumaratebusiness.industryMultiple sclerosismedicine.diseasechemistryRelapsing remittingNeurologySettore MED/26 - NeurologiaReal wordNeurology (clinical)business030217 neurology & neurosurgerydimethyl fumarate; efficacy; no evidence of disease activity 3; safety; teriflunomide
researchProduct

The parkin gene is not a major susceptibility locus for typical late-onset Parkinson's disease

2001

We investigated the parkin gene in 118 patients with typical Parkinson's disease (PD), i. e. in patients who had an onset of PD after the age of 45 years. The study group included 95 subjects with sporadic PD and 23 subjects from 18 families with autosomal recessive PD. No pathogenetic mutations in the parkin gene were detected either in familial or in sporadic patients. Our findings indicate that the parkin gene is not involved in the pathogenesis of classic late-onset PD.

Malemedicine.medical_specialtyNeurologyParkinson's diseaseUbiquitin-Protein LigasesDNA Mutational AnalysisMolecular Sequence DataLate onsetGenes RecessiveDermatologyDiseaseParkinPathogenesisLigasesParkinsonian DisordersmedicineHumansPoint MutationGenetic Predisposition to DiseaseGenetic TestingAge of OnsetAgedGeneticsbusiness.industryGeneral MedicineExonsParkin geneMiddle Agedmedicine.diseasenervous system diseasesPsychiatry and Mental healthSusceptibility locusChromosomes Human Pair 6FemaleNeurology (clinical)business
researchProduct

Vascular risk factors, white matter lesions and cognitive impairment in Parkinson’s disease: the PACOS longitudinal study

2020

Abstract Background Vascular risk factors (VRFs) may be associated with cognitive decline in early Parkinson’s disease (PD) but results are inconclusive. The identification of modifiable risk factors is relevant for prevention and treatment. Methods Parkinson’s disease (PD) patients of the PACOS cohort who underwent a baseline and follow-up neuropsychological evaluation were enrolled in the study. PD with Mild Cognitive Impairment (MCI) and dementia (PDD) were diagnosed according to the MDS criteria. A Baseline 1.5 T brain MRI was used to calculate the white matter lesions (WMLs) burden using the Wahlund visual scale. Laboratory data, presence of hypertension, diabetes and use of anti-hyper…

0301 basic medicinemedicine.medical_specialtyEpidemiologyNeuropsychological Testsbehavioral disciplines and activitiesWhite matter lesions03 medical and health sciences0302 clinical medicineInternal medicinemental disordersEpidemiologyHumansMedicineDementiaCognitive DysfunctionLongitudinal StudiesRisk factorCognitive declineOriginal CommunicationFramingham Risk Scorebusiness.industryMild cognitive impairmentParkinson DiseaseEpidemiology Hypertension Mild cognitive impairment Parkinson’s disease Risk factors White matter lesions Humans Longitudinal Studies Neuropsychological Tests Risk Factors Cognitive Dysfunction Parkinson Disease White Mattermedicine.diseaseWhite MatterHyperintensitynervous system diseases030104 developmental biologyBlood pressureRisk factorsNeurologyHypertensionCohortParkinson’s diseaseNeurology (clinical)business030217 neurology & neurosurgeryJournal of Neurology
researchProduct

Clinical Correlates of Functional Motor Disorders: An Italian Multicenter Study

2020

Background\ud Functional motor disorders (FMDs) are abnormal movements that are significantly altered by distractive maneuvers and are incongruent with movement disorders seen in typical neurological diseases.\ud \ud Objective\ud The objectives of this article are to (1) describe the clinical manifestations of FMDs, including nonmotor symptoms and occurrence of other functional neurological disorders (FND); and (2) to report the frequency of isolated and combined FMDs and their relationship with demographic and clinical variables.\ud \ud Methods\ud For this multicenter, observational study, we enrolled consecutive outpatients with a definite diagnosis of FMDs attending 25 tertiary movement …

0301 basic medicineWeaknessPediatricsmedicine.medical_specialtyMovement disordersfunctional neurological disordersdiagnosisPopulationfunctional weakneDisease030105 genetics & heredityfunctional weakness03 medical and health sciences0302 clinical medicinefunctional neurological disordermedicineeducationResearch Articleseducation.field_of_studyfunctional neurological disorders; functional dystonia; functional tremor; functional weakness; diagnosisbusiness.industryfunctional neurological disorders functional dystonia functional tremor functional weakness diagnosisFunctional weaknessfunctional dystoniatremorNeurologyMulticenter studyAnxietyfunctional tremorSettore MED/26 - NeurologiaObservational studydystoniaNeurology (clinical)medicine.symptombusinessfunctional neurological disorders functional dystonia functional tremor functional weakness diagnosis.030217 neurology & neurosurgery
researchProduct

Frequency and Correlates of Subjective Memory Complaints in Parkinson’s Disease with and without Mild Cognitive Impairment: Data from the Parkinson’s…

2018

Subjective memory complaints (SMC) may represent the preclinical phase of mild cognitive impairment (MCI) due to Alzheimer's disease. Dementia/MCI have been described with a high prevalence in Parkinson's disease (PD), but whether SMC may predict the development of cognitive impairment has been barely explored. To evaluate the frequency and clinical correlates of isolated SMC (PD-SMC) or within the construct of MCI in subjects with PD, 147 PD patients from the PArkinson's disease COgnitive impairment Study (PACOS) were consecutively recruited for the study. This is a multicenter study involving two Movement Disorder Centers in south Italy. All subjects underwent comprehensive neuropsycholog…

Male0301 basic medicineParkinson's diseaseParkinson's diseaseDiseaseNeuropsychological TestsAnxietyLogistic regressionExecutive Function0302 clinical medicineSurveys and QuestionnairesAttentionCognitive impairmentAged 80 and overGeneral NeuroscienceNeuropsychologyParkinson DiseaseGeneral MedicineMiddle Agedmusculoskeletal systemPsychiatry and Mental healthClinical PsychologyVisual Perceptioncardiovascular systemAnxietySettore MED/26 - NeurologiaFemaleAnxiety; cognitive impairment; disability; motor impairment; Parkinson's disease; subjective complaints; Neuroscience (all); Clinical Psychology; Geriatrics and Gerontology; Psychiatry and Mental Healthmedicine.symptommedicine.medical_specialtyStatistics Nonparametricmotor impairment03 medical and health sciencesInternal medicinemental disordersmedicineHumansDementiaAgedRetrospective Studiescognitive impairmentSubjective complaints Cognitive Impairment Parkinson’s Disease Disability Motor Impairment AnxietyMemory DisordersNeuroscience (all)subjective complaintsbusiness.industrymedicine.diseaseCross-Sectional Studies030104 developmental biologydisabilityEtiologyGeriatrics and GerontologyCognition Disordersbusiness030217 neurology & neurosurgeryJournal of Alzheimer's Disease
researchProduct

Retinal Thickness and Microvascular Pattern in Early Parkinson's Disease.

2020

A thinning of intraretinal layers has been previously described in Parkinson's disease (PD) patients compared to healthy controls (HCs). Few studies evaluated the possible correlation between retinal thickness and retinal microvascularization. Thus, here we assessed the thickness of retinal layers and microvascular pattern in early PD patients and HCs, using, respectively, spectral-domain optical coherence tomography (SD-OCT) and SD-OCT-angiography (SD-OCT-A), and more interestingly, we evaluated a possible correlation between retinal thickness and microvascular pattern. Patients fulfilling criteria for clinically established/clinically probable PD and HCs were enrolled. Exclusion criteria …

0301 basic medicineSystemic diseasemedicine.medical_specialtyretinaParkinson's diseasegenetic structuresNerve fiber layeroptical coherence tomography angiographylcsh:RC346-42903 medical and health scienceschemistry.chemical_compound0302 clinical medicinevascularizationOphthalmologyMedicinelcsh:Neurology. Diseases of the nervous systemOriginal ResearchRetinaoptical coherence tomographybusiness.industryMicrovascular DensityRetinalmedicine.diseaseInner plexiform layereye diseases030104 developmental biologymedicine.anatomical_structurechemistryNeurologyInner nuclear layerparkinson's diseaseNeurology (clinical)sense organsbusiness030217 neurology & neurosurgeryoptical coherence tomography; optical coherence tomography angiography; parkinson's disease; retina; vascularizationFrontiers in neurology
researchProduct

An exploration of anger phenomenology in multiple sclerosis

2009

Background and purpose:  Multiple sclerosis (MS) patients are often emotionally disturbed. We investigated anger in these patients in relation to demographic, clinical, and mood characteristics. Patients and methods:  About 195 cognitively unimpaired MS patients (150 relapsing–remitting and 45 progressive) were evaluated with the State Trait Anger Expression Inventory, the Chicago Multiscale Depression Inventory, and the State Trait Anxiety Inventory. The patients’ anger score distribution was compared with that of the normal Italian population. Correlation coefficients among scale scores were calculated and mean anger scores were compared across different groups of patients by analysis of …

business.industryMultiple sclerosismedia_common.quotation_subjectAngermedicine.diseasebehavioral disciplines and activitiesCorrelationMoodNeurologymental disordersbehavior and behavior mechanismsmedicineAnxietyNeurology (clinical)Analysis of variancemedicine.symptomPrefrontal cortexbusinesspsychological phenomena and processesState-Trait Anxiety InventoryClinical psychologymedia_commonEuropean Journal of Neurology
researchProduct